Clinical trials: Leukemia, Lymphoblastic
Chronic Lymphocytic Leukemia (CLL)
Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)
Chronic lymphocytic leukemia (CLL) is the most common leukemia (cancer of blood cells). The purpose of this study is to assess retreatment with venetoclax-obinutuzumab (VenG) in participants previously treated with fixed duration…
- Trial name
- ReVenG (NCT04895436)
- Testing
- Venetoclax, Obinutuzumab
- Where
- 58 sites in United States, Australia and 9 more
- Volunteers
- 75 people
- Sponsor
- AbbVie
Precursor Cell Lymphoblastic Leukemia-lymphoma
Intravenous Ixazomib in Pediatric Participants With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LLy)
The purpose of this study is to determine the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D), safety and toxicity, and pharmacokinetics (PK) of ixazomib administered intravenously in combination with…
- Trial name
- NCT03888534
- Testing
- Ixazomib
- Where
- 7 sites in United States, Spain
- Sponsor
- Millennium Pharmaceuticals, Inc.
Relapsed/Refractory, High Risk Hematologic Malignancies, T-ALL/Lymphoma
CD7 CAR-T Cell Treatment of Relapsed/Refractory CD7+ T -Acute Lymphoblastic Leukemia/ Lymphoma
This is a phase I, interventional, single arm, open label, treatment study to evaluate the safety and tolerability of CD7 CAR-T cells in patients with relapsed and/or refractory, high risk hematologic malignancies.
- Trial name
- NCT05212584
- Testing
- CD7CAR T cells
- Where
- China
- Volunteers
- 24 people
- Sponsor
- iCell Gene Therapeutics
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
A Study of CG-806 in Patients With Relapsed or Refractory CLL/SLL or Non-Hodgkin's Lymphomas
This study is being done to evaluate the safety, tolerability and effectiveness of Oral CG-806 for the treatment of patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), or Non-Hodgkin's Lymphomas…
- Conditions
- Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Non-Hodgkin's Lymphoma
- Trial name
- NCT03893682
- Testing
- CG-806
- Where
- 30 sites in United States
- Volunteers
- 36 people
- Sponsor
- Aptose Biosciences Inc.
Leukemia
Fludarabine and Cyclophosphamide With or Without Oblimersen in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Oblimersen may help fludarabine and cyclophosphamide kill more cancer cells by making them more sensitive to…
- Trial name
- NCT00024440
- Testing
- filgrastim, oblimersen sodium, cyclophosphamide
- Where
- United States
- Sponsor
- Genta Incorporated
Leukemia, Lymphocytic, Chronic, B-Cell
Intravenous BI 836826 in Combination With Ibrutinib in Relapsed/Refractory CLL Patients Who Have Been Pre-treated With at Least One Prior Line of Systemic Therapy, and Who Are Eligible for Treatment With Ibrutinib
Intravenous BI 836826 in combination with ibrutinib in relapsed/refractory Chronic Lymphocytic Leukemia (CLL) patients who have been pre-treated with at least one prior line of systemic therapy, and who are eligible for treatment…
- Trial name
- NCT02759016
- Testing
- BI 836826, Ibrutinib
- Where
- 3 sites in United States
- Volunteers
- 7 people
- Sponsor
- Boehringer Ingelheim
B-Cell Chronic Lymphocytic Leukemia
Interaction Study of Ibrutinib and Cytochrome P450 (CYP) 3A Inhibitors in Participants With B-cell Malignancy
The purpose of this study is to assess the effect of a moderate Cytochrome P450 (CYP) 3A inhibitor (erythromycin) and a strong CYP3A inhibitor (voriconazole) on the steady-state pharmacokinetics (PK [the study of the way a drug…
- Trial name
- NCT02381080
- Testing
- Ibrutinib, Erythromycin, Voriconazole
- Where
- 6 sites in Canada, Russia and 1 more
- Volunteers
- 26 people
- Sponsor
- Janssen Research & Development, LLC
Relapsed or Refractory Lymphoma Including ENKL
A Phase 1b/2 Study of Intravenous Brincidofovir in Patients With Relapsed or Refractory Lymphoma and Relapsed or Refractory Extranodal Natural Killer/T-cell Lymphoma
This study is a multi-center, global, open-label, Phase 1b/2 clinical study, and it will be conducted at multiple study sites in several countries, including Japan, Korea, and Singapore, to reveal the safety, tolerability, dose…
- Trial name
- NCT06761677
- Testing
- Brincidofovir
- Where
- 8 sites in China, Japan and 1 more
- Volunteers
- 43 people
- Sponsor
- SymBio Pharmaceuticals
Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia
Expanded Access Protocol - Blinatumomab in Pediatric & Adolescent Subjects With Relapsed/Refractory B-precursor ALL
Primary Objective: To estimate the incidence of treatment-emergent and treatment-related adverse events during treatment with blinatumomab in pediatric and adolescent subjects with B-precursor ALL in second or later bone marrow…
- Trial name
- RIALTO (NCT02187354)
- Testing
- Blinatumomab, Extension of LTFU as per ProtocolAmendment7 7Jun18
- Where
- 19 sites in United States, Austria and 5 more
- Sponsor
- Amgen
Chronic Lymphocytic Leukemia
Safety and Efficacy of the Combination of Tirabrutinib and Entospletinib With and Without Obinutuzumab in Adults With Chronic Lymphocytic Leukemia (CLL)
The primary objective of this study is to determine the preliminary efficacy of the combination of tirabrutinib (formerly GS-4059) and entospletinib with obinutuzumab in adults with relapsed or refractory chronic lymphocytic…
- Trial name
- NCT02983617
- Testing
- Tirabrutinib, Entospletinib, Obinutuzumab
- Where
- 15 sites in Germany
- Volunteers
- 36 people
- Sponsor
- Gilead Sciences
CLL (Chronic Lymphocytic Leukemia), SLL (Small Lymphocytic Lymphoma)
A Phase Ib Study of the Selective PKC-β Inhibitor MS-553 in Patients With Refractory or Relapsed CLL/SLL
A Phase Ib Study of the Selective PKC-β Inhibitor MS-553 in Patients with Refractory or Relapsed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Trial name
- NCT06979076
- Testing
- MS-553, DS1, MS-553, DS2
- Volunteers
- 12 people
- Sponsor
- MingSight Pharmaceuticals, Inc
CLL/SLL, NHL
HMPL-760 Safety and Tolerability Study in Patients With Previously Treated CLL/SLL or NHL
An open label single-arm clinical trial to evaluate the safety, tolerability, PK, PD, and preliminary efficacy of HMPL-760 in patients with previously treated CLL/SLL or NHL
- Conditions
- CLL/SLL, NHL, MCL, MZL
- Trial name
- NCT05176691
- Testing
- HMPL-760
- Where
- 36 sites in United States, Australia and 5 more
- Sponsor
- Hutchmed
Lymphoma, Non-Hodgkin, Chronic Lymphocytic Leukemia
A Study of JNJ-64264681 and JNJ-67856633 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia
The primary purpose of this study is to determine: the recommended Phase 2 doses (RP2Ds) of JNJ-64264681 and JNJ 67856633 when administered together in participants with B cell non-Hodgkin lymphoma (NHL) and chronic lymphocytic…
- Trial name
- NCT04657224
- Testing
- JNJ-64264681, JNJ-67856633
- Where
- 28 sites in United States, Australia and 10 more
- Volunteers
- 75 people
- Sponsor
- Janssen Research & Development, LLC
B Cell Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia
Escalating Dose Study in Subjects With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia
The purpose of this study is to evaluate the safety and tolerability of AVL-292 as monotherapy in subjects with relapsed or refractory B cell non-Hodgkin lymphoma (B-NHL), chronic lymphocytic leukemia (CLL) or Waldenstrom's…
- Conditions
- B Cell Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, Waldenstrom Macroglobulinemia
- Trial name
- NCT01351935
- Testing
- AVL-292
- Where
- 13 sites in United States
- Volunteers
- 113 people
- Sponsor
- Celgene
CD7-positive Relapsed/Refractory T Lymphoblastic Leukemia/Lymphoma
PA3-17 Injection in Adult Patients With CD7-positive Relapsed/Refractory T-lymphoblastic Leukemia/Lymphoma
Translation: This clinical trial is designed as a single-arm, open-label, multicenter study. After signing the informed consent form, eligible subjects will undergo a single nucleated cell collection for the preparation of CAR-T…
- Trial name
- NCT07188610
- Testing
- T cell injection targeting CD7 chimeric antigen receptor
- Where
- 16 sites in China
- Volunteers
- 100 people
- Sponsor
- PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Chronic Lymphocytic Leukemia, B-cell Lymphomas
Safety, Tolerability and PK of BTK Inhibitor DTRMWXHS-12 in Patients With B-Cell Lymphomas
The Primary Objective is to evaluate the safety and tolerability of multiple dose oral administration of DTRMWXHS-12 capsule in patients with B-cell lymphoma.
- Trial name
- NCT02891590
- Testing
- DTRMWXHS-12
- Where
- China
- Volunteers
- 13 people
- Sponsor
- Zhejiang DTRM Biopharma
Leukaemia, Lymphocytic, Chronic
Ofatumumab Maintenance Treatment vs No Further Treatment in Relapsed CLL Responding to Induction Therapy
The purpose of this study was to determine if maintenance therapy with ofatumumab would prolong remission in patients with CLL who have responded to second or third line treatment.
- Trial name
- PROLONG (NCT01039376)
- Testing
- Ofatumumab, Observation
- Where
- 203 sites in United States, Argentina and 23 more
- Volunteers
- 480 people
- Sponsor
- Novartis Pharmaceuticals
Leukemia, Lymphoblastic, Acute, T-cell, Myelogenous Leukemia
A Notch Signalling Pathway Inhibitor for Patients With T-cell Acute Lymphoblastic Leukemia/Lymphoma (ALL)(0752-013)
A Notch signalling pathway inhibitor study in pediatric and adult patients with relapsed (worsening) or refractory (not responding to treatment) T-cell acute lymphoblastic leukemia/lymphoma (T-ALL).
- Conditions
- Leukemia, Lymphoblastic, Acute, T-cell, Myelogenous Leukemia, Chronic Lymphocytic Leukemia, Myelodysplastic Syndromes
- Trial name
- NCT00100152
- Testing
- MK0752, (Notch Inhibitor)
- Volunteers
- 50 people
- Sponsor
- Merck Sharp & Dohme LLC
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
ACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (BTK) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia, Richter's Syndrome or Prolymphocytic Leukemia
This study is evaluating the safety and efficacy of a new BTK inhibitor, acalabrutinib, for the treatment of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).
- Conditions
- Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Richter's Syndrome, Prolymphocytic Leukemia
- Trial name
- NCT02029443
- Testing
- Acalabrutinib
- Where
- 12 sites in United States, Italy and 1 more
- Volunteers
- 306 people
- Sponsor
- Acerta Pharma BV
Chronic Lymphocytic Leukemia, CLL
A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.
The purpose of this study is to establish the safety of novel dosing and ramp-up schedules for sonrotoclax in participants with hematological malignancies.
- Conditions
- Chronic Lymphocytic Leukemia, CLL, Mantle Cell Lymphoma, MCL
- Trial name
- NCT06697184
- Testing
- Sonrotoclax, Zanubrutinib
- Where
- 22 sites in United States, Australia and 4 more
- Volunteers
- 258 people
- Sponsor
- BeOne Medicines